Cohance to discuss Q2 and H1 FY27 results on 6 November 2026

Board & Shareholder Meetings View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.8%Reaction day

₹463.45

prior close

₹471.60

announcement price

In-mkt

timing

Nifty Smallcap 250marketpendingvs market: pending

Pharmaceuticals peers, median of 173sector+2.0%+1.9% vs sector

On the reaction day the stock moved 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.9

10m

+1.7

15m

+1.8

30m

+1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.8pendingpending+2.0+1.9

Next day

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences Limited has scheduled a conference call for investors and analysts on Friday, 6 November 2026 at 6:30 pm IST. The company will announce its unaudited results for the quarter and half year ended 30 September 2026 earlier that day. Senior management will give an initial discussion, followed by an investor and analyst question-and-answer session. The filing provides call access and registration details, but no financial results or operating figures.

Likely market impact

The call may clarify performance after results are released. No financial figures are provided, so there is no direct impact on reported results.